Frontiers | Natural killer cell engagers for cancer immunotherapy

1 Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United States 2 Cancer Pharmacology Program, Cancer Institute of New Jersey, New Brunswick, NJ, United States This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over convent ional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicit

Read the full article here

Source: www.frontiersin.org

Categories: Hem/Oncs, General Medicine News

Tweets with this article

David A. Russler-Germain

RT @LabWaggoner: Review: NK cell engagers for cancer immunotherapy https://t.co/WdQ9XJjQDO https://t.co/Um9KXXrTZ2

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates…

Dan Kaufman February 8, 2025

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates…

Dan Kaufman February 7, 2025

Frontiers | Executive function, limbic circuit dynamics and repetitive and restricted behaviors in children with autism spectrum disorder

1 Peking University Sixth Hospital, Peking University Institute of Mental Health, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), NHC Key Laboratory…

Frontiers in Neuroscience February 7, 2025

Judge temporarily blocks Trump administration from placing 2,200 USAID workers on paid leave

A federal judge has temporarily blocked the Trump administration from placing 2,200 employees of the U.S. Agency for International Development on paid leave. U.S.

Gary Lyman February 7, 2025

Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1…

Vivek Subbiah, MD February 7, 2025

Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes – OncoDaily

Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes / Brittany L. Bychkovsky, cancer, Cancer Phenotypes, Carolyn Horton, Colin

Sara Tolaney February 7, 2025

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis

All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along…

Mudit Chowdhary, MD February 7, 2025

Related Articles